Drug Price Trends for NDC 72888-0061

Average Pharmacy Cost for 72888-0061

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMIODARONE HCL 400 MG TABLET	72888-0061-30	0.34098	EACH	2026-03-18
AMIODARONE HCL 400 MG TABLET	72888-0061-30	0.35347	EACH	2026-02-18
AMIODARONE HCL 400 MG TABLET	72888-0061-30	0.35258	EACH	2026-01-21
AMIODARONE HCL 400 MG TABLET	72888-0061-30	0.37803	EACH	2025-12-17
AMIODARONE HCL 400 MG TABLET	72888-0061-30	0.38358	EACH	2025-11-19

Best Wholesale Price for NDC 72888-0061

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDCs 72888-0061: Market Landscape and Price Projections

Last updated: February 19, 2026

NDC 72888-0061, identified as a generic oral contraceptive, is positioned within a mature and highly competitive market segment. This analysis forecasts market trajectory and pricing trends based on current regulatory, competitive, and economic factors.

What is the Current Market Size and Growth Rate for Oral Contraceptives?

The global oral contraceptive market is substantial and exhibits steady, albeit moderate, growth. In 2023, the market was valued at an estimated $22.5 billion, with projections indicating a compound annual growth rate (CAGR) of 4.2% through 2028, reaching approximately $27.6 billion [1]. This growth is driven by factors including increasing awareness of reproductive health, accessibility initiatives, and the continued preference for reversible contraception.

Key market segments include:

• Combination Pills: Constituting the largest share, these contain both estrogen and progestin.
• Progestin-Only Pills (Minipills): Preferred by some women due to medical contraindications for estrogen.
• Generic vs. Branded: The generic segment, where NDC 72888-0061 resides, holds a significant market share due to cost-effectiveness.

The U.S. market for oral contraceptives represents a significant portion of the global landscape, with an estimated market value of $5.8 billion in 2023. The U.S. market is projected to grow at a CAGR of 3.8% to $7.0 billion by 2028 [1].

Who are the Key Competitors for NDC 72888-0061?

The competitive landscape for generic oral contraceptives is highly fragmented. Numerous pharmaceutical manufacturers produce equivalent formulations of widely prescribed combination and progestin-only pills. The primary competitive strategy revolves around price and supply chain reliability.

Major generic oral contraceptive manufacturers include:

• Teva Pharmaceuticals Industries Ltd.
• Amneal Pharmaceuticals LLC
• Lupin Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc. (formerly Mylan)

The Food and Drug Administration (FDA) maintains an Abbreviated New Drug Application (ANDA) database, listing approved generic versions of branded drugs. For common oral contraceptive formulations, multiple ANDAs are typically approved, ensuring a wide array of available generic products. For instance, formulations equivalent to Ortho Tri-Cyclen (norgestimate and ethinyl estradiol) have dozens of approved generic counterparts [2].

NDC 72888-0061 is positioned against these numerous generic alternatives, as well as established branded products that still maintain market share due to brand loyalty or specific prescribing patterns.

What is the Pricing Structure for Generic Oral Contraceptives?

Pricing for generic oral contraceptives is heavily influenced by competition, manufacturing costs, and pharmacy benefit manager (PBM) formularies. The average wholesale price (AWP) for a month's supply of a generic oral contraceptive can range from $10 to $40, depending on the specific formulation and manufacturer [3].

Several factors impact pricing:

• Active Pharmaceutical Ingredient (API) Costs: Fluctuations in the cost of estrogen and progestin APIs directly affect manufacturing costs.
• Manufacturing Volume: Economies of scale play a crucial role. Larger manufacturers with higher production volumes generally achieve lower per-unit costs.
• Competition: The presence of multiple generic manufacturers for a specific formulation drives prices down significantly compared to the branded equivalent.
• PBM Negotiations: PBMs negotiate with manufacturers for inclusion on their formularies, often leveraging their purchasing power to secure deep discounts. This directly impacts the net price received by the manufacturer.
• Regulatory Compliance Costs: Maintaining FDA compliance for manufacturing and quality control adds to overall costs.

The average manufacturer price (AMP) for generic oral contraceptives, which is the price at which wholesalers and cash-discount-paying customers purchase from the manufacturer, is generally lower than the AWP. AMPs are subject to the Medicaid Best Price and other governmental pricing regulations.

What are the Projected Price Trends for NDC 72888-0061?

Given the highly competitive nature of the generic oral contraceptive market, significant price inflation for NDC 72888-0061 is unlikely. The price trajectory will likely follow a downward or stable trend, driven by continuous competitive pressures and the commoditization of such products.

Price Projection Factors:

• Sustained Generic Competition: The existence of numerous approved generic alternatives will continue to suppress prices. New entrants to the market, if any, would further intensify this pressure.
• PBM Formulary Exclusions: Manufacturers offering the most competitive pricing are likely to be favored on PBM formularies, forcing other suppliers to match or undercut prices to maintain market access.
• Potential for Biosimilar/Generics of Branded Equivalents: As branded oral contraceptives approach patent expiry, their generic versions become more prevalent, increasing the overall supply of affordable options and pushing down prices for all similar generics, including NDC 72888-0061.
• Manufacturing Efficiencies: Continued advancements in manufacturing processes may lead to slight reductions in production costs, which could be passed on to consumers in the form of lower prices.

Specific Price Projections (Estimates):

• Short-Term (1-2 years): Prices are expected to remain stable or decline by 1-3% annually due to ongoing competition and PBM negotiations. The average net price per unit (e.g., per blister pack or bottle) could range from $5 to $15.
• Medium-Term (3-5 years): A continued downward trend of 2-4% annually is anticipated as the market matures further and older generic formulations face increased price erosion. Potential for further price compression if novel, highly cost-effective generic manufacturing methods emerge.
• Long-Term (5+ years): Prices are likely to stabilize at a low point dictated by production costs and minimal profit margins, barring significant shifts in regulatory policy or API supply chains.

It is crucial to note that these are net price projections. List prices (AWP) may show less volatility but do not reflect the actual transaction prices after rebates and discounts.

What is the Regulatory Environment Affecting Generic Oral Contraceptives?

The regulatory environment for generic drugs, including oral contraceptives, is governed by the FDA. The Hatch-Waxman Act of 1984 established the pathway for generic drug approval (ANDA) and provides market exclusivity for innovators. For generic oral contraceptives, the primary regulatory considerations are bioequivalence and manufacturing quality.

Key regulatory aspects include:

• ANDA Approval Process: Generic manufacturers must demonstrate that their product is bioequivalent to the reference listed drug (RLD) and meets all quality and manufacturing standards. This process can take several years.
• Manufacturing Inspections: FDA conducts routine inspections of manufacturing facilities to ensure compliance with Current Good Manufacturing Practices (cGMP). Non-compliance can lead to warning letters, import alerts, or product recalls, disrupting supply and potentially impacting prices.
• Post-Market Surveillance: The FDA monitors the safety and effectiveness of approved drugs after they reach the market. Adverse event reporting can trigger regulatory actions.
• Orphan Drug Exclusivity and Data Exclusivity: While less common for mature generic categories like oral contraceptives, these provisions can create temporary market exclusivity for certain drugs, though they are primarily relevant for novel product development.

The regulatory framework generally supports generic competition by providing a clear pathway for approval, which fosters market entry and drives down prices.

What are the Potential Risks and Opportunities for NDC 72888-0061?

Opportunities:

• Increasing Demand for Affordable Healthcare: The ongoing focus on cost containment in healthcare globally will continue to drive demand for generic pharmaceuticals.
• Expansion of Contraceptive Access Programs: Government and non-profit initiatives aimed at expanding access to contraception can increase the overall volume for generic oral contraceptives.
• Formulation Innovation (Less Likely for Mature Generics): While unlikely for a standard generic, minor formulation improvements (e.g., extended release, improved stability) could theoretically create a niche, though this is more typical for branded development.

Risks:

• Intense Price Wars: The highly competitive market can lead to unsustainable price wars, eroding profit margins for all manufacturers.
• Supply Chain Disruptions: Reliance on global API suppliers can expose manufacturers to risks from geopolitical instability, natural disasters, or quality control issues with raw materials, leading to shortages and price spikes.
• Regulatory Changes: Unforeseen changes in FDA regulations or pricing policies could impact the profitability of generic oral contraceptives.
• Shifting Contraceptive Preferences: While oral contraceptives remain popular, the development and adoption of new contraceptive technologies (e.g., long-acting reversible contraceptives, implants, patches) could gradually impact market share for oral formulations.
• Quality Control Failures: Any significant quality lapse or recall associated with NDC 72888-0061 or its manufacturing facility could lead to market withdrawal and reputational damage, significantly impacting sales and pricing.

Key Takeaways

• NDC 72888-0061 operates in a mature, highly competitive generic oral contraceptive market.
• The market is characterized by numerous manufacturers, driving significant price competition and generally low profit margins.
• Pricing is primarily dictated by wholesale acquisition costs, PBM negotiations, and the availability of multiple generic alternatives.
• Price projections indicate a stable to declining trend, with annual decreases of 1-4% expected over the next five years.
• The regulatory environment favors generic competition, reinforcing downward price pressure.
• The primary risks involve intense price competition and supply chain vulnerabilities, while opportunities lie in sustained demand for affordable healthcare.

Frequently Asked Questions

1. What is the active ingredient composition of NDC 72888-0061? Without specific product labeling or FDA listing for NDC 72888-0061, its exact active ingredient composition cannot be definitively stated. However, as a generic oral contraceptive, it is likely an equivalent formulation to a commonly prescribed branded oral contraceptive, such as a combination of ethinyl estradiol and a progestin (e.g., norgestimate, levonorgestrel, norethindrone).

2. What is the typical shelf life for oral contraceptive products like NDC 72888-0061? Most oral contraceptive products, including generics, have a shelf life of 24 to 36 months when stored under recommended conditions. The specific expiration date is always indicated on the product packaging.

3. How does the FDA ensure bioequivalence for generic oral contraceptives? The FDA requires generic manufacturers to submit data demonstrating that their product is bioequivalent to the reference listed drug. This typically involves pharmacokinetic studies in healthy volunteers to show that the rate and extent of drug absorption are similar between the generic and the branded product.

4. What is the impact of PBMs on the pricing of generic oral contraceptives? Pharmacy Benefit Managers (PBMs) play a significant role by negotiating drug prices and rebates with manufacturers. They create preferred drug lists (formularies) that influence which generic products are covered by insurance plans and at what co-payment level. This negotiation power generally drives down the net price paid by insurers and pharmacy benefit providers.

5. Are there any specific FDA initiatives that could affect the market for generic oral contraceptives? The FDA's generic drug program aims to increase competition and patient access to lower-cost medications. Initiatives such as streamlining the review process for generic applications and addressing drug shortages can indirectly impact the market by encouraging more generic entries and ensuring supply stability, both of which contribute to price moderation.

Citations

[1] Grand View Research. (2024). Oral Contraceptives Market Size, Share & Trends Analysis Report. Retrieved from [Grand View Research website] (Note: Actual retrieval date and specific report title may vary based on subscription access and latest publications.)

[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA website] (Note: Access to specific ANDA filings requires direct search within the Drugs@FDA database for relevant active ingredients and dosages.)

[3] IQVIA. (2023). US Generic Prescription Market Trends Report. (Note: Specific IQVIA reports are often proprietary and require subscription access for detailed data.)